Development of a New Pre- and Post-Processing Tool (SADAPT-TRAN) for Nonlinear Mixed-Effects Modeling in S-ADAPT
Journal Title: The AAPS Journal - Year 2011, Vol 13, Issue 2
Abstract
The online version of this article (doi:10.1208/s12248-011-9257-x) contains supplementary material, which is available to authorized users.
Authors and Affiliations
Jurgen Bernd Bulitta, Ayhan Bingölbali, Beom Soo Shin, Cornelia Barbara Landersdorfer
Keywords
Related Articles
- EP ID EP681303
- DOI 10.1208/s12248-011-9257-x
- Views 100
- Downloads 0
Fish drug analysis—Phish-pharm: A searchable database of pharmacokinetics data in fish
Information about drug residues and pharmacokinetic parameters in aquatic species is relatively sparse. In addition, it is difficult to rapidly compare data between studies due to differences in experimental conditions,...
Does the Systemic Plasma Profile Inform the Liver Profile? Analysis Using a Physiologically Based Pharmacokinetic Model and Individual Compounds
The online version of this article (doi:10.1208/s12248-016-9895-0) contains supplementary material, which is available to authorized users.
Assessment of the Impact of Dosing Time on the Pharmacokinetics/Pharmacodynamics of Prednisolone
Prednisolone is widely used for the treatment of inflammation and auto-immune diseases. It exhibits nonlinear pharmacokinetics (PK); and its induced systemic effects (pharmacodynamics (PD)) are commonly evaluated with tw...
Specific Method Validation and Sample Analysis Approaches for Biocomparability Studies of Denosumab Addressing Method and Manufacture Site Changes
The online version of this article (doi:10.1208/s12248-012-9414-x) contains supplementary material, which is available to authorized users.
Intranasal Delivery of Proteins and Peptides in the Treatment of Neurodegenerative Diseases
The blood–brain barrier (BBB) is a major impediment to the therapeutic delivery of peptides and proteins to the brain. Intranasal delivery often provides a non-invasive means to bypass the BBB. Advantages of usin...